1. Home
  2. HOWL
  3. HOWL News

Latest Werewolf Therapeutics Inc. (HOWL) News on November 27, 2025

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
HOWL

GlobeNewswire

20 days ago

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

HOWL

MT Newswires

22 days ago

Wedbush Halves Price Target on Werewolf Therapeutics to $3 From $6, Keeps Outperform Rating

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
HOWL

GlobeNewswire

23 days ago

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
HOWL

Zacks

a month ago

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
HOWL

Zacks

a month ago

Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised

BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
HOWL

Zacks

a month ago

BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
HOWL

Zacks

a month ago

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
HOWL

Zacks

a month ago

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

HOWL

MT Newswires

2 months ago

Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
HOWL

GlobeNewswire

2 months ago

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
HOWL

Zacks

3 months ago

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?

Werewolf Therapeutics to Participate in the BIO International Convention
HOWL

GlobeNewswire

5 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
HOWL

Zacks

6 months ago

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
HOWL

GlobeNewswire

6 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

HOWL

GlobeNewswire

6 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
HOWL

GlobeNewswire

6 months ago

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024)
HOWL

Simply Wall St.

7 months ago

Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024)

HOWL

MT Newswires

7 months ago

Wedbush Adjusts Price Target on Werewolf Therapeutics to $6 From $8, Maintains Outperform Rating

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
HOWL

GlobeNewswire

7 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
HOWL

GlobeNewswire

7 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics to Participate in Upcoming Investor Conferences
HOWL

GlobeNewswire

7 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
HOWL

Zacks

7 months ago

Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
HOWL

GlobeNewswire

7 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
HOWL

GlobeNewswire

8 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
HOWL

Simply Wall St.

9 months ago

Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
HOWL

GlobeNewswire

9 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
HOWL

GlobeNewswire

9 months ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Pacira (PCRX) Tops Q4 Earnings Estimates
HOWL

Zacks

9 months ago

Pacira (PCRX) Tops Q4 Earnings Estimates

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
HOWL

GlobeNewswire

9 months ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch
HOWL

Simply Wall St.

9 months ago

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Werewolf Therapeutics provides business update, highlights 2025 outlook
HOWL

TipRanks

10 months ago

Werewolf Therapeutics provides business update, highlights 2025 outlook

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
HOWL

GlobeNewswire

10 months ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
HOWL

TipRanks

a year ago

Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

HOWL

MT Newswires

a year ago

Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating

Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
HOWL

Simply Wall St.

a year ago

Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
HOWL

Zacks

a year ago

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

HOWL

MT Newswires

a year ago

Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
HOWL

GlobeNewswire

a year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
HOWL

Zacks

2 years ago

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
HOWL

Zacks

2 years ago

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%

Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
HOWL

Simply Wall St.

2 years ago

Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
HOWL

Zacks

2 years ago

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Dave's Repurchase of FTX Convertible Note for $71 Million Finalized
HOWL

PR Newswire

2 years ago

Dave's Repurchase of FTX Convertible Note for $71 Million Finalized

HOWL

GlobeNewswire

2 years ago

RGC Resources, Inc. Schedules First Quarter 2024 Earnings Call

Investors Could Be Concerned With Utah Medical Products' (NASDAQ:UTMD) Returns On Capital
HOWL

Simply Wall St.

2 years ago

Investors Could Be Concerned With Utah Medical Products' (NASDAQ:UTMD) Returns On Capital

It Might Not Be A Great Idea To Buy Ames National Corporation (NASDAQ:ATLO) For Its Next Dividend
HOWL

Simply Wall St.

2 years ago

It Might Not Be A Great Idea To Buy Ames National Corporation (NASDAQ:ATLO) For Its Next Dividend

Third Coast Bancshares Inc (TCBX) Reports Record 2023 Earnings, Net Income Surges 79%
HOWL

GuruFocus.com

2 years ago

Third Coast Bancshares Inc (TCBX) Reports Record 2023 Earnings, Net Income Surges 79%

Grindrod Shipping Holdings Ltd. Announces Ship Sales
HOWL

GlobeNewswire

2 years ago

Grindrod Shipping Holdings Ltd. Announces Ship Sales

Piedmont Lithium Inc. (PLL) Stock Drops Despite Market Gains: Important Facts to Note
HOWL

Zacks

2 years ago

Piedmont Lithium Inc. (PLL) Stock Drops Despite Market Gains: Important Facts to Note

Chuck Royce Increases Stake in Identiv Inc
HOWL

GuruFocus.com

2 years ago

Chuck Royce Increases Stake in Identiv Inc

Why WW International Stock Bounced 6% Higher Today
HOWL

Motley Fool

2 years ago

Why WW International Stock Bounced 6% Higher Today

ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains
HOWL

Simply Wall St.

2 years ago

ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains

Heron Therapeutics, Inc. (NASDAQ:HRTX) is largely controlled by institutional shareholders who own 52% of the company
HOWL

Simply Wall St.

2 years ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) is largely controlled by institutional shareholders who own 52% of the company

Hot Stocks Roundup: Why Are People Talking About WW International and Zoom Video Communications Stocks Right Now?
HOWL

Motley Fool

2 years ago

Hot Stocks Roundup: Why Are People Talking About WW International and Zoom Video Communications Stocks Right Now?

Dave Inc.'s (NASDAQ:DAVE) market cap up US$26m last week, benefiting both retail investors who own 41% as well as insiders
HOWL

Simply Wall St.

2 years ago

Dave Inc.'s (NASDAQ:DAVE) market cap up US$26m last week, benefiting both retail investors who own 41% as well as insiders

ESS Expands Deployment Footprint in California, Commissions New Project and Advances Energy Center Product Line
HOWL

Business Wire

2 years ago

ESS Expands Deployment Footprint in California, Commissions New Project and Advances Energy Center Product Line

Blade Air Mobility to Present at 26th Annual Needham Growth Conference
HOWL

GlobeNewswire

2 years ago

Blade Air Mobility to Present at 26th Annual Needham Growth Conference

Despegar.com, Corp. (NYSE:DESP) is largely controlled by institutional shareholders who own 55% of the company
HOWL

Simply Wall St.

2 years ago

Despegar.com, Corp. (NYSE:DESP) is largely controlled by institutional shareholders who own 55% of the company

Institutions own 39% of Orange County Bancorp, Inc. (NASDAQ:OBT) shares but individual investors control 39% of the company
HOWL

Simply Wall St.

2 years ago

Institutions own 39% of Orange County Bancorp, Inc. (NASDAQ:OBT) shares but individual investors control 39% of the company

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable
HOWL

Simply Wall St.

2 years ago

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable

What Makes FinWise Bancorp (FINW) a Good Fit for 'Trend Investing'
HOWL

Zacks

2 years ago

What Makes FinWise Bancorp (FINW) a Good Fit for 'Trend Investing'

Gambling.com Group to Participate at 26th Annual Needham Growth Conference on January 18
HOWL

Business Wire

2 years ago

Gambling.com Group to Participate at 26th Annual Needham Growth Conference on January 18

Luna to Present at Needham Growth Conference
HOWL

Business Wire

2 years ago

Luna to Present at Needham Growth Conference

HOWL

Business Wire

2 years ago

Franklin Universal Trust ("FT" or the "Fund") Announces Distribution

RCA Accessories To Expand its Presence in the Multi-Billion-Dollar Over-the-Counter Hearing Aid Market with the Launch of Three New Premium RCA Models
HOWL

PR Newswire

2 years ago

RCA Accessories To Expand its Presence in the Multi-Billion-Dollar Over-the-Counter Hearing Aid Market with the Launch of Three New Premium RCA Models

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Hallador Energy (HNRG): The Biggest Contributor of Cove Street Capital
HOWL

Insider Monkey

2 years ago

Hallador Energy (HNRG): The Biggest Contributor of Cove Street Capital

RGC Resources, Inc.'s (NASDAQ:RGCO) largest shareholders are retail investors with 45% ownership, institutions own 36%
HOWL

Simply Wall St.

2 years ago

RGC Resources, Inc.'s (NASDAQ:RGCO) largest shareholders are retail investors with 45% ownership, institutions own 36%

VALNEVA - Declaration of shares and voting rights: December 31, 2023
HOWL

GlobeNewswire

2 years ago

VALNEVA - Declaration of shares and voting rights: December 31, 2023

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares
HOWL

GlobeNewswire

2 years ago

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
HOWL

GlobeNewswire

2 years ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

VOXX INTERNATIONAL CORPORATION SETS DATE FOR ITS FISCAL 2024 THIRD QUARTER RESULTS AND CONFERENCE CALL
HOWL

PR Newswire

2 years ago

VOXX INTERNATIONAL CORPORATION SETS DATE FOR ITS FISCAL 2024 THIRD QUARTER RESULTS AND CONFERENCE CALL

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
HOWL

PR Newswire

2 years ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
HOWL

Zacks

2 years ago

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why

Melt Pharmaceuticals Provides Corporate Update
HOWL

Business Wire

2 years ago

Melt Pharmaceuticals Provides Corporate Update

Perfect Corp. Announces Final Results of Previously Announced Self Tender Offer to Purchase up to 16,129,032 Class A Ordinary Shares for an Aggregate Purchase Price of up to $50,000,000
HOWL

Business Wire

2 years ago

Perfect Corp. Announces Final Results of Previously Announced Self Tender Offer to Purchase up to 16,129,032 Class A Ordinary Shares for an Aggregate Purchase Price of up to $50,000,000

HOWL

Business Wire

2 years ago

Franklin Universal Trust ("FT" or the "Fund") Announces Notification of Sources of Distributions

Saratoga Investment Corp. to Report Fiscal Third Quarter 2024 Financial Results and Hold Conference Call
HOWL

GlobeNewswire

2 years ago

Saratoga Investment Corp. to Report Fiscal Third Quarter 2024 Financial Results and Hold Conference Call

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
HOWL

GlobeNewswire

2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Luna Announces $50 Million Strategic Investment from White Hat Capital Partners
HOWL

Business Wire

2 years ago

Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

Jefferies initiates coverage on Chewy, other pet stocks
HOWL

Yahoo Finance Video

2 years ago

Jefferies initiates coverage on Chewy, other pet stocks

HOWL

Reuters

2 years ago

UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study

Share on Social Networks: